Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 24.4% in December

Invivyd, Inc. (NASDAQ:IVVD) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 35,613,115 shares, a growth of 24.4% from the December 15th total of 28,634,579 shares. Approximately 20.5% of the company’s stock are short sold. Based on an average trading volume of 5,706,265 shares, the days-to-cover ratio is currently 6.2 days. Based on an average trading volume of 5,706,265 shares, the days-to-cover ratio is currently 6.2 days. Approximately 20.5% of the company’s stock are short sold.

Insider Activity at Invivyd

In other Invivyd news, Director Kevin F. Mclaughlin bought 50,000 shares of Invivyd stock in a transaction that occurred on Wednesday, November 19th. The stock was acquired at an average price of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director owned 50,000 shares of the company’s stock, valued at $125,000. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 25.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently bought and sold shares of IVVD. SG Americas Securities LLC acquired a new position in shares of Invivyd during the 4th quarter worth approximately $60,000. Catalyst Funds Management Pty Ltd bought a new stake in shares of Invivyd in the second quarter valued at approximately $27,000. Vanguard Personalized Indexing Management LLC grew its position in Invivyd by 238.6% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock worth $29,000 after buying an additional 28,146 shares in the last quarter. Bank of America Corp DE increased its stake in Invivyd by 330.5% during the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company’s stock worth $54,000 after acquiring an additional 37,811 shares during the period. Finally, Jefferies Financial Group Inc. bought a new position in Invivyd during the 3rd quarter worth $102,000. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Trading Down 0.6%

Shares of NASDAQ:IVVD traded down $0.02 during trading on Tuesday, reaching $2.44. 424,929 shares of the stock were exchanged, compared to its average volume of 2,862,300. The firm has a market cap of $567.65 million, a PE ratio of -5.20 and a beta of 0.61. Invivyd has a 12 month low of $0.35 and a 12 month high of $3.07. The stock has a 50-day moving average price of $2.41 and a 200-day moving average price of $1.60.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The firm had revenue of $13.13 million during the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative net margin of 119.63% and a negative return on equity of 92.97%. On average, sell-side analysts expect that Invivyd will post -1.64 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IVVD has been the subject of a number of recent research reports. BTIG Research initiated coverage on shares of Invivyd in a research note on Monday, December 22nd. They set a “buy” rating and a $10.00 price objective for the company. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a report on Thursday, November 13th. D. Boral Capital restated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. Finally, Cantor Fitzgerald started coverage on shares of Invivyd in a report on Monday, October 6th. They set an “overweight” rating and a $10.00 target price on the stock. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Invivyd currently has an average rating of “Hold” and an average price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.